beceltinib

Beceltinib (BS-1101) is an orally bioavailable, irreversible covalent inhibitor of Bruton's tyrosine kinase (BTK) being developed by Hangzhou Biosun Pharmaceutical. It is primarily under investigation for the treatment of persistent or chronic primary immune thrombocytopenia (ITP) and various B-cell malignancies. By forming a covalent bond with the BTK enzyme, beceltinib inhibits B-cell receptor (BCR) signaling and Fcγ receptor-mediated signaling in macrophages, which are critical pathways in the pathogenesis of ITP and B-cell proliferation. Clinical data from Phase 1/2 trials in ITP patients have shown that beceltinib can effectively increase platelet counts with a manageable safety profile, predominantly consisting of mild adverse events.